APA (7th ed.) Citation

Quinn, D. I., Tsao-Wei, D. D., Twardowski, P., Aparicio, A. M., Frankel, P., Chatta, G., . . . Newman, E. (2021). Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. Investigational new drugs, 39(3), 812-820. https://doi.org/10.1007/s10637-020-01038-6

Chicago Style (17th ed.) Citation

Quinn, David I., et al. "Phase II Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in Recurrent or Metastatic Transitional Cell Carcinoma of the Urothelium – an NCI-CTEP Sponsored: California Cancer Consortium Trial, NCI 6879." Investigational New Drugs 39, no. 3 (2021): 812-820. https://doi.org/10.1007/s10637-020-01038-6.

MLA (9th ed.) Citation

Quinn, David I., et al. "Phase II Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in Recurrent or Metastatic Transitional Cell Carcinoma of the Urothelium – an NCI-CTEP Sponsored: California Cancer Consortium Trial, NCI 6879." Investigational New Drugs, vol. 39, no. 3, 2021, pp. 812-820, https://doi.org/10.1007/s10637-020-01038-6.